In order to boost its T-cell engager portfolio, Takeda has entered into a license agreement with F-star Therapeutics to research, develop and commercialise a bispecific antibody against an immuno-oncology target. Takeda has agreed to pay US$1 M upfront and committed up to US$40 M more to access F-star’s Fcab™ and mAb2™ technology platforms. The deal comes one month after a subsidiary of Sino Biopharmaceuticals, InoX Pharma, announced its planned acquisition of F-star in a US$161 M buyout.